Can a common Alzheimer's drug prevent delirium relapse in poisoning patients?
NCT ID NCT06399679
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether rivastigmine, a drug used for Alzheimer's, can prevent delirium from coming back after initial treatment with physostigmine for anticholinergic poisoning. About 42 people aged 10 and older with controlled delirium will receive either rivastigmine or a placebo. The goal is to see if rivastigmine reduces the chance of delirium recurrence.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Rivastigmine
- What this could lead to
- If it works, this could provide a longer-lasting treatment option to prevent delirium from returning after initial poisoning control.
- What could go wrong
- This is a very small, early-phase trial that is currently suspended. Results may not apply to all poisoning cases, and rivastigmine may not work better than placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTICHOLINERGIC TOXICITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.